US 12,440,530 B2
Skin solution with solubilized bakuchiol
Felipe Jimenez, Rialto, CA (US); Lyndon Garcines, Fountain Valley, CA (US); Susan Goldsberry, Huntington Beach, CA (US); and Senad Ibrulj, Santa Ana, CA (US)
Assigned to ENVY MEDICAL, INC., North Chicago, IL (US)
Filed by Envy Medical, Inc., North Chicago, IL (US)
Filed on Oct. 3, 2023, as Appl. No. 18/376,038.
Application 18/376,038 is a continuation of application No. 15/257,318, filed on Sep. 6, 2016, abandoned.
Application 15/257,318 is a continuation of application No. 14/692,718, filed on Apr. 21, 2015, granted, now 9,433,587, issued on Sep. 6, 2016.
Application 14/692,718 is a continuation in part of application No. 13/783,066, filed on Mar. 1, 2013, granted, now 9,295,723, issued on Mar. 29, 2016.
Claims priority of provisional application 61/982,229, filed on Apr. 21, 2014.
Prior Publication US 2024/0139269 A1, May 2, 2024
Int. Cl. A61K 9/00 (2006.01); A61K 8/34 (2006.01); A61K 8/9789 (2017.01); A61K 9/06 (2006.01); A61K 31/045 (2006.01); A61K 31/05 (2006.01); A61K 31/07 (2006.01); A61K 31/19 (2006.01); A61K 31/203 (2006.01); A61K 31/327 (2006.01); A61K 31/4436 (2006.01); A61K 31/60 (2006.01); A61K 31/7048 (2006.01); A61K 31/7056 (2006.01); A61K 36/487 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61Q 19/00 (2006.01)
CPC A61K 36/487 (2013.01) [A61K 8/34 (2013.01); A61K 8/347 (2013.01); A61K 8/9789 (2017.08); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/07 (2013.01); A61K 31/19 (2013.01); A61K 31/203 (2013.01); A61K 31/327 (2013.01); A61K 31/4436 (2013.01); A61K 31/60 (2013.01); A61K 31/7048 (2013.01); A61K 31/7056 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61Q 19/00 (2013.01); A61K 2236/00 (2013.01)] 9 Claims
 
1. A topical composition comprising:
(i) about 0.05 wt % to about 2.00 wt % of bakuchiol;
(ii) about 0.05 wt % to about 2.00 wt % of bisabolol;
(iii) about 0.5 wt % to about 2.00 wt % of salicylic acid;
(iv) about 4.8 wt % to about 22 wt % of decyl glucoside;
(v) one or more skin conditioners;
(vi) Perilla ocymoides leaf extract;
(vii) Olea europaea extract; and
(viii) about 70 wt % to about 99 wt % water.